Zentalis closes 26,450,000-share public offering at $3.5 per share, raises $92.6 million gross

Reuters2026/08/17 20:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zentalis closed an underwritten public offering of 26,450,000 common shares at USD 3.5 each.
Underwriters fully exercised a 3,450,000-share option; gross proceeds totaled about USD 92.6 million.
Net proceeds earmarked for development of azenosertib, including clinical work, manufacturing, regulatory support, working capital.
TD Cowen, Guggenheim Securities, Oppenheimer served as joint bookrunners; H.C. Wainwright was passive bookrunner.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608171601PRIMZONEFULLFEED9811490) on August 17, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Zentalis closes 26,450,000-share public offering at $3.5 per share, raises $92.6 million gross

You may also like

Crypto prices